US6919086B1 - Graminae pollen allergen mutants for specific immunotherapy, and production and use of the same - Google Patents

Graminae pollen allergen mutants for specific immunotherapy, and production and use of the same Download PDF

Info

Publication number
US6919086B1
US6919086B1 US09/381,903 US38190300A US6919086B1 US 6919086 B1 US6919086 B1 US 6919086B1 US 38190300 A US38190300 A US 38190300A US 6919086 B1 US6919086 B1 US 6919086B1
Authority
US
United States
Prior art keywords
seq
modified recombinant
allergen
gramineae
allergens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/381,903
Other languages
English (en)
Inventor
Helga Kahlert
Hans-Thomas Stüwe
Helmut Fiebig
Oliver Cromwell
Wolf-Meinhard Becker
Albrecht Bufe
Gabriele Schramm
Lothar Jäger
Wolf-Dieter Müller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Assigned to MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG reassignment MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BECKER, WOLF-MEINHARD, BUFE, ALBRECHT, CROMWELL, OLIVER, FIEBIG, HELMUT, JAGER, LOTHAR, KAHLERT, HELGA, MULLER, WOLF-DIETER, SCHRAMM, GABRIELE, STUWE, HANS-THOMAS
Application granted granted Critical
Publication of US6919086B1 publication Critical patent/US6919086B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to modified recombinant allergens (mra) which are derived from allergens which can be obtained from natural raw materials by extraction. Pollen grains from Gramineae, such as Phleum pratense, Lolium perenne, Dactylus glomerata, Poa pratensis, Cynodon dactylon and Holcus lanatus, inter alia, are used as the natural raw material.
  • Gramineae such as Phleum pratense, Lolium perenne, Dactylus glomerata, Poa pratensis, Cynodon dactylon and Holcus lanatus, inter alia, are used as the natural raw material.
  • Extracts of Gramineae pollen consist of a heterogeneous mixture of proteins in glycoproteins, some of which react with IgE antibodies of allergic patients and are termed allergens by definition.
  • allergens The molecular properties of these allergens enable them to be classified into 6 groups, in association with which the cross-reactivity of the Gramineae species in question is relatively high.
  • the dominant allergen groups are groups 5 and 1, in accordance with the customary allergen classification (Liebers et al., Clin. Exper. Allergy, 26, 494-516 (1996)).
  • N-terminal amino acid sequences and/or the partial or complete deduced amino acid sequences of groups 5 and 1 of the main allergens are known (Vrtala et al., J. Immunology 151, 4773-4781 (1993) and Bufe et al. FEBS. Lett. 263, 6-12 (1995)). Furthermore, methods for cloning these main allergens have been described (Scheiner et al. Int. Arch Allergy Immuno. 98, 93-96 (1992)).
  • aqueous extracts of Gramineae pollen are used for the in-vitro diagnosis of type 1 allergies. These extracts are also the basis for in-vitro diagnosis and subsequent specific immunotherapy (Fiebig H., Allergo Journal 7, 377-382 (1995)).
  • the use of native allergen extracts for specific immunotherapy is restricted by the IgE-dependent, allergic reactions (side reactions) which are induced under these circumstances. For this reason, native allergen extracts can only be administered in doses which are below the side effect threshold.
  • the extracts are administered by means of several consecutive injections at a concentration which increases up to the maintenance dose. By means of adsorption onto gels, it is possible to use allergen extracts for hyposensitization in a manner which is more efficient and less subject to side effects.
  • allergoids which have a lower reactivity with IgE but which to a large extent retain their immunogenecity (Fiebig H., Allergo Journal 7, 377-382 (1995) and Maasch et al. Clin. Ref. Allergy 5, 89-106 (1987)).
  • modified recombinant allergens individual allergens, or defined mixtures, can be used as pharmaceuticals for the hyposensitization in accordance with the individual sensitization spectrum.
  • the invention was based on the object of discovering novel compounds having valuable properties, in particular compounds which can be used for producing pharmaceuticals.
  • the compounds of the present invention in the form of the modified recombinant allergens and their salts and solvates, possess very valuable pharmacological properties while at the same time being well tolerated. In particular, they have a hyposensitizing effect.
  • the compounds can be used as pharmaceutical active compounds in human and veterinary medicine, in particular for therapy in association with allergic diseases and for hyposensitizing allergic patients.
  • the invention relates to modified recombinant allergens which are derived from allergens which are obtained from natural raw materials by extraction. Pollen grains from Gramineae, such as Phleum pratense, Lolium perenne, Dactylus glomerata, Poa pratensis, Cynodon dactylon and Holcus lanatus, inter alia, are used as the natural raw material.
  • the invention relates to modified recombinant allergens which are derived from the main allergens of groups 1-6 and whose reactivity with the IgE antibodies of patients who are allergic to grass pollen is eliminated or at least reduced while that with the T lymphocytes is still retained.
  • the modified recombinant allergens differ from the wild type in that the genes for the allergens have been modified by genetic manipulation methods such that the polypeptides which they encode exhibit substitutions, deletions and/or additions of individual or several amino acids as compared with the wild type.
  • the dominant T cell-reactive regions of the modified recombinant allergens are not altered by genetic manipulation.
  • the modified recombinant allergens are derived from the main allergens of group 5 or else of group 1.
  • the novel allergens are derived from the main Phl p 5b allergen.
  • Phl p 5b Using the single-letter code for amino acids, the sequence of Phl p 5b is as follows:
  • the invention particularly relates to modified recombinant allergens in which at least one, or a combination, of the regions 16-42, 135-149 and 180-206 of the Phl p 5b polypeptide, consisting of a total of 265 amino acids, is/are not altered.
  • the segments to be preserved are the T cell epitope regions.
  • the said amino acid residues can also be derivatized. Modifications of the side chains are particularly appropriate in this context.
  • amino acids are able to occur in several enantiomeric forms, all these forms, and also their mixtures (e.g. the DL forms), are included both in that which is stated above and in that which follows.
  • amino acids can, for example as constituents of compounds, be provided with appropriate protecting groups which are known per se.
  • prodrug derivatives i.e. compounds which are modified with, for example, alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the organism to form the active novel compounds, are also included in the novel compounds.
  • prodrugs also include biodegradable polymer derivatives of the novel compound as described, for example, in Int. J. Pharm. 115, 61-67 (1995).
  • novel allergens may possess one or more chiral centres and therefore occur in different stereoisomeric forms.
  • the present invention encompasses all these forms.
  • modified recombinant allergens which are derived from the following group of polypeptides, which are derived from Phl p 5b:
  • PM1 denotes point mutation 1 and has the following sequence (the amino acids which are replaced as compared with Phl p 5b are printed in bold):
  • the other particularly preferred peptides have the following sequences:
  • This sequence corresponds to that of DM2 where, however, the amino acids of positions 179-217 of the starting peptide Phl p 5b additionally exhibit an altered sequence and all the subsequent amino acids are missing.
  • DM3 ( ⁇ A 254 ⁇ T 177 , A 120 ⁇ T): ADAGYAPATPAAAGAAAGKATTEEQKLIEDINVGFKAAVAAAASVPAADK 1 10 20 30 40 50 FKTFEAAFTSSSKAAAAKAPGLVPKLDAAYSVAYKAAVGATPEAKFDSFV 51 60 70 80 90 100 ASLTEALRVIAGALEVHAVKPVTEEPGMAKIPAGELQIIDKIDAAFKVAA 101 110 120 130 140 150 TAAGGAYDTYKCIPSLEAAVKQAYAATVAAAPQVKYAVFEAALTKTITAMS 151 160 170 180 190 200 EVQKVSQPATGAATVAAGAATTAAGAASGAATVAAGGYKV 202 210 220 230 240 (SEQ ID NO 93)
  • the invention furthermore relates to a process for preparing modified recombinant allergens by using the polymerase chain reaction and/or its variants.
  • the allergens can also be prepared by means of methods of peptide synthesis which are known per se, e.g. the modified Merrifield technique, as described in the literature (e.g. in the standard works such as Houben-Weyl), Methoden der organischen Chemie (Methods of Organic Chemistry), Georg-Thieme-Verlag, Stuttgart;), under reaction conditions which are known and are suitable for the said reactions.
  • use can also be made of variants which are known per se but which are not mentioned here in detail.
  • Preferred starting compounds for the solvolysis or hydrogenolysis are those which, in place of one or more free amino and/or hydroxyl groups contain corresponding protected amino and/or hydroxyl groups, preferably those which, in place of an H atom which is connected to an N atom, carry an amino protecting group, e.g. those which, in place of an NH 2 group, contain an NHR′ group (in which R′ is an amino protecting group, e.g. BOC or CBZ).
  • Starting compounds are also preferred which, in place of the H atom of a hydroxyl group, carry a hydroxyl protecting group, e.g. those which, in place of a hydroxyphenyl group, contain an R′′O-phenyl group (in which R′′ is a hydroxyl protecting group).
  • amino protecting group is known generally and refers to groups which are suitable for protecting (blocking) an amino group from chemical reactions but which can be removed readily after the desired chemical reaction has been carried out at other sites of the molecule.
  • Typical groups of this nature are, in particular, unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups. Since the amino protecting groups are removed after the desired reaction (or reaction sequence) has taken place, their nature and size is otherwise not critical; however, those amino protecting groups are preferred which have 1-20, in particular 1-8, C atoms.
  • acyl group is to be interperted in the widest possible sense.
  • acyl groups which are derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and, in particular, alkoxycarbonyl, aryloxycarbonyl and, especially, aralkoxycarbonyl groups.
  • acyl groups of this nature are alkanoyl, such as acetyl, propionyl or butyryl; aralkanoyl, such as phenylacetyl; aroyl, such as benzoyl or toluoyl; aryloxyalkanoyl, such as POA; alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC or 2-iodoethoxycarbonyl; aralkyloxycarbonyl, such as CBZ (“carbobenzoxy”), 4-methoxybenzyloxycarbonyl or FMOC; arylsulfonyl, such as Mtr.
  • Preferred amino protecting groups are BOC and Mtr, and also CBZ, Fmoc, benzyl and acetyl.
  • hydroxyl protecting group is likewise known generally and refers to groups which are suitable for protecting a hydroxyl group from chemical reactions but which can readily be removed after the desired chemical reaction has been carried out at other sites of the molecule. Typical groups of this nature are the abovementioned unsubstituted or substituted aryl, aralkyl or acyl groups and also alkyl groups. The nature and size of the hydroxyl protecting groups is not critical since they are removed once again after the desired chemical reaction or reaction sequence has taken place; groups having 1-20, in particular 1-10, C atoms are preferred.
  • hydroxyl protecting groups are, interalia, benzyl, p-nitrobenzoyl, p-toluenesulfonyl, tert-butyl and acetyl, with benzyl and tert-butyl being particularly preferred.
  • the COOH groups in aspartic acid and glutamic acid are preferably protected in the form of their tert-butyl esters (e.g. Asp (OBut)).
  • the compounds are liberated from their functional derivatives using, for example, strong acids, expediently using TFA or perchloric acid, but also using other strong inorganic acids, such as hydrochloric acid or sulfuric acid, strong organic carboxylic acids, such as trichloroacetic acid, or sulfonic acids, such as benzenesulfonic acid or p-toluenesulfonic acid. It is possible, but not always necessary, for a supplementary inert solvent to be present.
  • strong acids expediently using TFA or perchloric acid
  • other strong inorganic acids such as hydrochloric acid or sulfuric acid
  • strong organic carboxylic acids such as trichloroacetic acid
  • sulfonic acids such as benzenesulfonic acid or p-toluenesulfonic acid. It is possible, but not always necessary, for a supplementary inert solvent to be present.
  • Preferred suitable inert solvents are organic, for example carboxylic, acids, such as acetic acid, ethers, such as tetrahydrofuran or dioxane, amides, such as DMF, halogenated hydrocarbons, such as dichloromethane, and, in addition, also alcohols, such as methanol, ethanol or isopropanol, and water. Mixtures of the abovementioned solvents are also suitable. TFA is preferably used in excess without the addition of another solvent; perchloric acid is used in the form of a mixture consisting of acetic acid and 70% perchloric acid in a ratio of 9:1.
  • the reaction temperatures for the cleavage are expediently between about 0° and 50°; the reaction is preferably carried out between 15 and 30° or room temperature.
  • the BOC, OBut and Mtr groups can, for example, be preferably eliminated using TFA in dichloromethane or using approximately 3 to 5N HCl in dioxane at 15-30°; the FMOC group can be eliminated using an approximately 5 to 50% solution of dimethylamine, diethylamine or piperadine in DMF at 15-30°.
  • the trityl group is employed for protecting the amino acids histidine, asparagine, glutamine and cysteine. Depending on the desired end product, it is eliminated using TFA/10% thiophenol, with the trityl group being eliminated from all the amino acids mentioned, or using TFA/anisole or TFA/thioanisole, in which case the trityl group is only eliminated from His, Asn and Gln and remains on the Cys side chain.
  • Protecting groups which can be removed hydrogenolytically can be eliminated, for example, by treatment with hydrogen in the presence of a catalyst (e.g. a precious metal catalyst such as palladium, expediently on a support such as carbon).
  • a catalyst e.g. a precious metal catalyst such as palladium, expediently on a support such as carbon.
  • Suitable solvents in this context are the abovementioned solvents, in particular, for example, alcohols, such as methanol or ethanol, or amides, such as DMF.
  • the hydrogenolysis is carried out at temperatures of between about 0 and 100° and under pressures of between about 1 and 200 bar, preferably at 20-30° and under 1-10 bar.
  • Hydrogenolysis of the BZ group is, for example, effected satisfactorily on 5 to 10% Pd/C in methanol or using ammonium formate (instead of hydrogen) on Pd/C in methanol/DMF at 20-30°.
  • An acid can be used to convert a base into the affiliated acid addition salt, for example by reacting equivalent quantities of the base and the acid in an inert solvent, such as ethanol, and then concentrating by evaporation. Acids which yield physiologically harmless salts are particularly suitable for this reaction.
  • inorganic acids for example sulfuric acid, nitric acid, hydrohalic acids, such as hydrochloric acid or hydrobromic acid, phosphoric acids, such as orthophosphoric acid, or sulfamic acid, and also organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic monobasic or polybasic carboxylic, sulfonic or sulfuric acids, for example formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methanesulfonic or ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic
  • an acid of the formula I can be converted into one of its physiologically harmless metal or ammonium salts by reacting it with a base.
  • suitable salts are, in particular, the sodium, potassium, magnesium, calcium and ammonium salts, and also substituted ammonium salts, e.g. the dimethyl-, monoethyl-, diethyl- or diisopropyl-ammonium salts, cyclohexyl, or dicyclohexyl-ammonium salts, or dibenzylethylenediammonium salts, and, furthermore, salts with arginine or lysine, for example.
  • the allergenic constituents of the extracts which have been prepared by means of customary methods, are identified and their important physiocochemical parameters are characterized.
  • Constituents are identified as being allergens by demonstrating their ability to bind to the IgE antibodies of allergic patients. As a rule, this is done using methods which are known per se, such as SDS-PAGE, isoelectrofocusing and then Western blotting with sera from allergic patients, with only the binding antibodies of the IgE isotype being developed. In this context, care has to be taken to ensure that an adequately large number of types of clinically verified allergic patients (a value of 20 should be set as being the lowest number) are used. Other methods, such as CIE or CRIE, can also be used as alternatives.
  • These Gramineae pollen allergens which have been identified and characterized in this way can be prepared analytically such that it is possible to carry out an N-terminal amino acid determination. Furthermore, the allergens can also be purified biochemically and used for preparing monoclonal antibodies. These monoclonal antibodies can, like the IgE antibodies in the sera of allergic patients, be used for the immunological identification and characterization of the allergens from natural sources or of the molecules which are prepared by the recombinant technique.
  • oligopeptides Based on the amino acid sequence, a series of overlapping oligopeptides is prepared by means of customary methods, such as solid phase synthesis using modified Merrifield techniques, with the entire sequence of the allergens being covered. Oligopeptides having in each case 6-20, preferably 9-15, amino acid residues may suitably be prepared in this context. Dodecapeptides which are offset by in each case 3 amino acids and which cover the entire sequence of the respective allergen in an overlapping manner are very particularly suitable.
  • T cell clones from patients who are allergic to Gramineae pollen are established by repeated stimulation with the purified, natural or recombinantly prepared allergen in question using the customary method (Lit). For this, it is necessary to establish a representative number of T cell clones which derive from a sufficiently large number of donors.
  • T cell clones are incubated with the above-described overlapping peptides and the ability of the latter to stimulate the T cells to proliferate is tested.
  • the proliferation is determined by incorporating [ 3 H]-thymidine by means of methods which are customary per se.
  • Those oligopeptides which induce adequate proliferation of the T cell clones are then regarded as peptide ligands which correspond to the T cell epitopes.
  • the T cell epitopes which have been determined in this manner are used to define T cell-reactive regions of the allergens which, for their part, constitute the basis for constructing the novel modified recombinant allergens.
  • the primary structures of the T-cell-reactive regions which encompass the immunodominant T cell epitopes are partially or completely excluded from alterations.
  • Genetic manipulation is used to perform mutations in the DNA sequence underlying the remaining regions of the polypeptides (allergens) in order to process an altered primary structure.
  • This altered primary structure destroys or limits the ability of sequence-dependent continuous B cell epitopes to bind to the IgE antibodies and, due to the formation of a modified tertiary structure as a consequence of the primary modification, completely or partially abolishes the ability of conformation-dependent, possibly discontinuous epitopes to react with their antibodies.
  • the mutations can be replacements of individual or several amino acids outside the T cell-reactive regions.
  • Such point mutations are introduced into the DNA, which, for example, encodes rPhl p 5b, by means of site-specific mutagenesis using the polymerase chain reaction (PCR).
  • the plasmid pGS13, an expression vector (pMalc) which contacts the cDNA for rPhl p 5b, can be used as the template in this context.
  • Gene-specific primers which contain appropriate base replacements and also a new restriction site (Nhe I or Sph I) are used for the PCR.
  • the fragments which are amplified in the PCR and which carry the mutation are ligated one after the other into a cloning vector and the complete product is then recloned into the pMalc expression vector.
  • mutations can be performed by means of differentially arranged deletions.
  • truncated 3′-terminal fragments of the cDNA of rPHl p 5b are prepared in a PCR using gene-specific primers.
  • Relatively large 3′-terminal fragments are removed from the starting vectors (pGS12 or pGS13) by means of restriction at internal cleavage sites and the fragments which were amplified in the PCR, and which are in each case smaller, are ligated in to replace them.
  • mutations involving additions of one or more amino acids can be produced by inserting additional DNA fragments.
  • the DNA clones which have been mutated by means of genetic manipulation and which encode modified recombinant allergens are recloned into suitable expression vectors and expressed in suitable host organisms.
  • the fusion proteins are purified in a customary manner from the supernatants or disruptions of these host organisms and, after the fusion moiety has been eliminated, the modified recombinant allergens are prepared in the pure state using customary biochemical methods. It is important that the modified recombinant allergens be used for further tests as pure components which correspond to the natural allergens.
  • the effects of the induced mutations on the allergenicity, i.e. the ability to bind to the IgE antibodies of allergic patients, of the modified recombinant allergens is determined qualitatively and quantitatively by means of the EAST inhibition test.
  • This assay shows whether a substance to be tested (modified recombinant allergen) is identical to, or different from, the natural allergen and/or the recombinant wild type. The extent of the immunochemical relatedness (cross reactivity) can also be quantified.
  • This EAST inhibition test only takes the reaction with IgE antibodies into account.
  • Those modified recombinant allergen variants which exhibit an inhibitory effect, measured as P rel at 50% inhibition, which is decreased at least by a factor of 10 2 as compared with the natural allergen and/or recombinant wild type are selected as being suitable.
  • the modified recombinant allergen variants which have been selected in this way are checked to see whether their T cell reactivity has in fact been retained. For this, a set of T cell clones which react with epitopes in the T cell-reactive regions are taken for testing in the first phase.
  • oligoclonal T cell lines which have been established by repeated stimulation with the relevant allergens, are employed for the testing.
  • SI stimulation index
  • polyclonal short-term T cell cultures from the peripheral blood of allergic patients are employed for testing.
  • the allergen-induced, IgE-mediated release of histamine by allergic effect or cells is of pathophysiological importance for the allergic reaction (side effect).
  • the reactivity of the effector cells (basophils and mast cells) and the epitope specificity of the IgE antibodies which are bound by way of Fc ⁇ RI are also of importance in this context.
  • the modified recombinant allergen variants are tested for their ability to induce histamine release by the degranulation of IgE-loaded basophils which are isolated from the blood of allergic patients.
  • the modified recombinant allergen variants which have been selected in accordance with the above selection regime have to exhibit a markedly reduced ability to release histamine.
  • the modified recombinant allergens which meet these requirements ensure reactivity with the majority of the TH cells which have a regulatory effect and, due to their diminished IgE reactivity, possess the requisite properties for being employed as therapeutic agents for the allergen-specific immunotherapy (hyposensitization) of patients who are allergic to Gramineae pollen.
  • the invention furthermore relates to pharmaceutical preparations which comprise one or more modified recombinant allergen(s) according to the present invention, and/or one of their physiologically harmless salts or solvates, and also, where appropriate, additional active compounds and/or auxiliary substances, for treating IgE-mediated allergies.
  • the invention furthermore relates to a process for producing pharmaceutical preparations, with at least one modified recombinant allergen and/or one of its physiologically harmless salts or solvates being brought into a suitable dosage from together with at least one solid, liquid or semiliquid carrier substance or auxiliary substance.
  • the invention furthermore relates to the use of the modified recombinant allergens and/or their physiologically harmless salts or solvates for producing pharmaceutical preparations, in particular by a non-chemical route.
  • they can be brought into a suitable dosage form together with at least one solid, liquid and/or semiliquid carrier substance or auxiliary substance and, where appropriate, in combination with one or more additional active component(s).
  • the pharmaceuticals are used for immunospecific therapy, i.e. for hyposensitization in association with allergies. It is likewise possible to conceive of using the modified recombinant allergens directly for the immunospecific therapy (hyposensitization) of allergies.
  • Suitable carrier substances are organic or inorganic substances which are suitable for enteral (e.g. oral), parenteral or topical administration or for administration in the form of an inhalation spray and which do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates, such as lactose and starch, magnesium stearate, talc or yellow soft paraffin.
  • Tablets, pills, coated tablets, capsules powders, granules, syrups, juices or drops are, in particular, employed for oral use, while suppositories are employed for rectal use, solutions, preferably oily or aqueous solutions and, in addition, suspensions, emulsions or implants are employed for parentreal use, and ointments, creams or powders are employed for topical use.
  • the novel compounds can also be lyophilized and the resulting lyophilates can, for example, be used to produce preparations for injection.
  • the cited preparations can be sterilized and/or comprise auxiliary substances, such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffering substances, dyes, flavourants and/or several additional active compounds, e.g. one or more vitamins.
  • auxiliary substances such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffering substances, dyes, flavourants and/or several additional active compounds, e.g. one or more vitamins.
  • auxiliary substances such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffering substances, dyes, flavourants and/or several additional active compounds, e.g. one or more vitamins.
  • sprays which comprise the active compound either dissolved or suspended in a propellant
  • the compounds and their physiologically harmless salts can be used for hyposensitizing allergic patients in association with controlling allergic diseases, in particular allergies which are provoked by grasses and grass pollen.
  • novel substances can, as a rule, be administered in analogy with other known, commercially available peptides, in particular, however, in analogy with the compounds which are discussed in U.S. Pat. No. 4,472,305, are preferably administered in doses of between about 0.05 and 500 mg, in particular of between 0.5 and 100 mg, per dosage unit.
  • the daily dose is preferably between about 0.01 and 2 mg/kg of bodyweight.
  • the special dose for each patient depends on a very wide variety of factors, for example on the efficacy of the special compound employed, on the age, bodyweight, general state of health and sex of the patient, on the diet, on the time and route of administration, on the rate of excretion, on the medicinal combination and on the severity of the particular disease to which the therapy applies. Parenteral administration is preferred.
  • FIG. 1 shows EAST inhibition curves of the Phl p 5b mutants using the allergic patient serum pool Bor 18/100.
  • the inhibitors are:
  • FIG. 2 shows EAST inhibition curves of the Phl p5b mutants using the allergic patient serum pool We 6.97.
  • the inhibitors are:
  • FIG. 3 shows EAST inhibition curves of the Phl p 5b mutants using the allergic patient serum pool 11/3.
  • FIG. 4 shows EAST inhibition curves of the Phl p 5b mutants using the allergic patient serum pool 11/12.
  • FIG. 5 shows EAST inhibition curves of the Phl p 5b mutants using the allergic patient serum pool 11/17.
  • FIG. 6 shows release of histamine from human basophils after reaction with the allergens and allergen mutants.
  • PBMC Peripheral mononuclear cells
  • APC autologous antigen-presenting cells
  • TCL blasts were enriched by means of density gradient centrifugation; the TCL which were obtained were then tested in a specific lymphocyte proliferation test (see Lit. 1 as well).
  • 2 ⁇ 10 4 /ml TCL blasts were in each case cultured with 5 ⁇ 10 4 /ml irradiated autologous APCs in triplicate samples in 96-well microculture plates. 10-20 ⁇ g of Phl p5 allergen were added as the specific antigen stimulus. After 56 hours of incubation, 3 H-labelled thymidine (1 ⁇ Ci/well) was pipetted into the microcultures.
  • the radioactivity which had been incorporated into the proliferating T cell blasts was measured in a beta counter (Matrix 96). The results were calculated, as the arithmetic mean of the multiple samples, in counts per minute (cpm).
  • the criterion for the quality of the TCL was the stimulation index, which was obtained by relating the cpm values with Phl p5 addition to those without Phl p5 addition.
  • TCLs were cloned (see Lit. 1).
  • 0.3 [lacuna] of TCL blasts/well were cultured in a final volume of 0.2 ml in 96-well microculture plates (round-bottomed) in the added presence of irradiated allogenic PBMC (5 ⁇ 10 4 /well), PHA (1.5 g/ml) and IL-2 (25 IU/ml).
  • PBMC irradiated allogenic PBMC
  • PHA 1.5 g/ml
  • IL-2 25 IU/ml
  • TCL TCL cloned
  • specificity of the isolated TCCs were determined as has just been described. Stimulation indices of at least 5 were rated as being positive for the TCCs.
  • the determination of T cell epitopes for defining the T cell-reactive regions on group 5 allergens was also carried out using specific proliferation tests, with 1-2 ⁇ g of synthesized dodecapeptide/ml being used for this purpose in each case (see below).
  • a total of 86 overlapping synthetic dodecapeptides which were prepared on the basis of the known primary structure of the Phl p 5b allergen as determined by Bufe et al. (Lit. 3), were used for determining the T cell epitopes. These peptides were prepared using a commercial synthesis kit supplied by CHIRON Mimotopes Peptide Systems/Clayton, Australia. The amino acid sequences of these peptides had a degree of overlap of 9 amino acids (Tab. 1). The reaction of TCC to one of the peptides used in the specific proliferation test was assessed as being positive when the calculated stimulation index was at least 5.
  • TCCs from 18 patients who were allergic to grass pollen were included in the investigations. From these, success was achieved in isolating 54 T cell clones which reacted specifically with the dodecapeptides which were based on the Phl p 5b sequence. Analysis of these TCCs shows that reconfiguration of peptide ligands is clearly concentrated in 3 immunodominant T cell-reactive regions. Of the 54 T cell clones, 46, corresponding to 85%, react with the peptides of the 3 immunodominant T cell-reactive regions A, B and C of Phl p 5b (Tab. 1a).
  • the immuno-dominant T cell-reactive region A encompasses a peptide (27 mer) which corresponds to positions 181-207 and which has a core region consisting of amino acids 181-195. 28 of the 54 Phl p 5b-reactive TCCs, corresponding to 51%, only react with this immunodominant region A .
  • TABLE 1a Mapping the T cell-reactive regions of the main grass pollen allergen Phl p 5 Immunodominant Stimulating T cell- peptide ligands reactive region TCC (12 mers)
  • a B C Minor epitope DW 8 139-150 + DW 14 196-207 + DW 16 181-192, 184-195 + DW 23 181-192 + DW 25 181-192, 184-195 + DW 28 184-195 + CBH 1 211-222, 214-225 + CBH 10 211-222 + JR 6a 22-33, 25-36 + JR 6b 136-147, 139-150 + JR 7a 28-39, 31-42 + JR 7b 136-147, 139-150 + JR 9 181-192, 184-195 + JR 10 19-30 + JR 11 49-60 + JR 13 181-192, 184-195 + JR 15 181-192, 184-195 + JR 19a 31-42 + JR 19b
  • Plasmid pGS13 was used as the starting vector. This is the pMalc vector (Biolabs) which contains the cDNA for the wt rPHl p 5b which is cloned between Bam EI and Hind III sites. Fragments 1 (bp: 1-153) and 2 (bp: 141-1374) of the cDNA for the rPHl p 5b were amplified in a PCR reaction. The following primers (restriction sites are underlined) were used for this reaction:
  • MP1 antisense 5′-GAAC GCTAGC GCCGCAGGGACGCTGGC-3′ (SEQ ID NO 95)
  • Phl p 5B antisense 5′-ATAT AAGCTT TCCTCTGAAGGAAGGCAACCC-3′ (SEQ ID NO 97)
  • the two mutagenesis primers Mp1 sense and MP1 antisense contain 6 base replacements which additionally give rise to a new restriction cleavage site for the enzyme Nhe I.
  • the amplified fragment 1 was digested with Bam HI and Nhe I and cloned into vector pUH89 (Jekel et al., Gene: 154: 55-59; 1995).
  • the resulting plasmid, pGS10 was restricted once again with Nhe I/Hind III, and fragment 2 (Nhe I/Hind III) was incorporated into these cleavage sites.
  • This plasmid, pGS11 comprises the complete cDNA encoding rPh1 p 5b but containing the desired base replacements.
  • the mutated cDNA was recloned between the Bam HI and Hind III cleavage sites of the expression vector pMalc.
  • the resulting plasmid was designated pGS21.
  • the point mutant rPhl p 5b PM1 was prepared in analogy with PM2. It contains, as the result of a PCR error, an additional point mutation N 32 ⁇ D.
  • PCysM1 5′ATA GGATCC ATCGAGGGTAGGGCCGATGCCGGCTACGCCCGGCCACCCCGGCT GCATG GGAGCG-3′ (SEQ ID NO 93)
  • Phl p 5b antisense see above.
  • the mutagenesis primer PCysM1 contains 3 base substitutions which lead to an alanine residue being replaced with a cysteine residue and which at the same time give rise to a new restriction cleavage site for the enzyme Sph I.
  • the PCR product was cloned directly into the pMalc expression vector (Bam HI/Hind III). The resulting vector was designated pCysM1. The success of the mutagenesis was checked in a restriction analysis using Sph I.
  • Plasmid pGS21 (see above) was used as the starting vector for cloning the deletion mutant DM1.
  • the bp 399-1374 fragment of the cDNA for rPhl p 5b was amplified in a PCR using the following primers:
  • Phl p 5b antisense see above.
  • Vector pGS21 was restricted with Nhe I and BamHI and separated from the excised fragment.
  • the PCR product which had also been restricted with Nhe I and BAM HI, was then ligated into the residual vector.
  • the vector which resulted from this, i.e. pDM1 contains the rPhl p 5b cDNA which has a deletion of 252 bp and which encodes the deletion mutant rPhl p 5bDMl.
  • Deletion mutants DM2 and DM3 were prepared in an analogous manner.
  • the binding of the allergens by the IgE antibodies is the basic prerequisite for the allergen-specific activation of the effector cells (mast cells, basophils, inter alia) in type I allergy.
  • the allergen-specific inhibition of the enzyme/allergen sorbent test is the best means for qualitatively and quantitatively recording the binding of the allergens to IgE anti-bodies.
  • the EAST inhibition test is carried out as follows. Microtitre plates are coated with allergen (natural or recombinant Ph1 p 5 or Ph1 p 5 b ) (1 ⁇ g/ml). After the unbound allergen molecules have been removed by washing, non-specific plastic binding sites are blocked with bovine serum albumin (0.5%).
  • Anti-IgE from allergic patients as a representative pool of 10-30 donors or as an individual serum, is incubated, in a suitable dilution, with the allergen-coated microtritre plates.
  • the bound allergen-specific IgE antibodies are quantified using enzyme-coupled anti-IgE antibodies (e.g. alk. phosphatase-a-IgE antibodies). This binding is inhibited by soluble allergen or the substance to be tested (allergen mutants) in dependence on the concentration.
  • the inhibition curve obtained with the purified natural allergen Ph1 p 5 b is used as the reference.
  • the inhibition curves depicted in FIG. 1 are obtained with the representative allergen patient serum pool Bor 18/100 (20 donors).
  • rPh1 p 5 b wild type
  • PM3 exhibit binding curves which are similar to that obtained with natural Ph1 p 5 b which has been purified by affinity chromatography. Minor differences are visible due to a better inhibitory effect in the lower range and to poorer inhibition at high concentrations. While the reason for this is unknown, it might be accounted for by confirmational epitopes which differ to a minor extent.
  • Point mutant PM1 exhibits this effect in the higher range to a somewhat greater degree.
  • Deletion mutants DM2 and DM2 + exhibit an extremely low inhibitory effect on the allergen-IgE reaction. This shows that the allergenicity of these mutants has to a large extent been eliminated. While a different serum pool from allergic patients (We 6/97) and also the individual sera from allergic patients II3, II12 and II17 exhibit sight variations in their inhibitory curves with the mutants, they nevertheless confirm that deletion mutants DM1 and DM3 exhibit greatly reduced allergenicity (FIGS. 2 - 5 ). Apart from a low residual activity, the inhibitory effect of deletion mutants DM2 and DM2 + is eliminated. Point mutations PM1 and PM3 exhibit either no reduction, or only a reduction which is for the most part slight, in allergenicity (e.g.
  • the inhibitory capacity of the modified allergens can be quantified by calculating the Prel values at 25% or 50% inhibition (1).
  • the corresponding inhibitory values, and also the allergenic potency (Prel) measured at 25 or 50% inhibition, are shown for the serum pools and the individual sera in Tables 2-6.
  • Deletion Mutants DM2 and DM2 + show their loss of allergenicity by their Prel values, which are extremely low or can no longer be determined in a meaningful manner. While point mutations PM1 and PM3 exhibit a partial loss of allergenicity, this loss is not adequate for practical use. Deletion mutants DM1 and DM3 exhibit a marked reduction in allergenicity. The reduction in IgE reactivity is superior to, or comparable with, that of the previously known chemically modified allergens and thereby makes these mutants particularly suitable candidates for immunotherapy.
  • the basophilic leucocytes from the EDTA blood of an allergic patient were first of all enriched by means of dextran sedimentation and then adjusted to a final concentration of 100,000 basophils/ml.
  • 200 ⁇ l of the cell suspension were in each case incubated, at 37° C. for 40 min, with 50 ⁇ l of antigen solution.
  • the rPh1 and p 5 b and the mutants were employed in varying concentrations (of 10 ⁇ 5 -10 ⁇ 12 M).
  • the histamine which was released was determined in the respective supernatants using the Pharmacia methylhistamine RIA in accordance with the manufacturer's instructions.
  • TCCs T cell clones
  • the TCCs derive from patients who are allergic to grass pollen (see Ex. 1) and are directed against the T cell-reactive regions A (FIG. 7 ), B ( FIG. 8 ) and C (FIG. 9 ).
  • the T cell reactivity was measured by stimulating the clones to proliferate. The results clearly show that the TCCs react specifically with the Ph1 p 5 b mutants when the relevant epitope is unaltered and, as expected, do not exhibit any reaction when the epitope is messing or is altered by a point mutation.
  • Stimulator 1 present UZH2 DW8 Medium ⁇ ⁇ ⁇ n Phl p5 + +++ +++ r Phl p5a ( ⁇ ) ⁇ +++ r Phl p5b + +++ + PM1 + +++ + PM3 + +++ ⁇ DM1 + +++ + DM2 ⁇ ⁇ ⁇ DM2 + ⁇ ⁇ ⁇ DM3 + +++ + PL (12 mer) + +++ +++ 1) Final concentration 0.3 ⁇ M 2) Stimulation index SI: ⁇ 1 ( ⁇ ), 1-2 (+), 2-5 (+), 5-10 (++), >10 (+++) 3) n.t.: not tested TABLE 9
  • TCLs The oligoclonal T cell lines (TCLs) from 8 patients who were allergic to grass pollen (see Ex. 1) were established by repeated activation with natural Ph1 p 5 b (a+b) or recombinant rPh1 p 5 b or 5 a+ 5 b.
  • the proliferative reaction of these TCLs was tested using the rPh1 p 5 b mutants (FIG. 10 ). This shows that while all the mutants activate the TCLs, there are quantitative differences.
  • the deletion mutant DM3 exhibits a strong specific stimulation with most of the TCLs.
  • T helper cells T helper cells from patients who are allergic to grass pollen.
  • TCLs T cell epitopes of the individual T cell clones
  • 3 immunodominant T cell-reactive regions which are recognized by 85% of the TCCs can be defined without difficulty (Example 1). It was possible to produce recombinant Ph1 p 5 b mutants by means of point mutations (Example 2) and by means of deletion mutations (Example 3).
  • the IgE reactivity of the point mutants (PM1 and PM3), as measured in the EAST inhibition test (Example 4), does not differ significantly from that of the wild-type Ph1 p 5 b. While the IgE reactivity of the deletion mutants DM1 and DM3 is greatly reduced, it is still detectable. By contrast, the IgE binding of mutants DM2 and DM2 + is very greatly reduced. This gradual decrease in the allergenicity of the rPh1 p 5 b mutants is also confirmed by the histamine release test using spec. IgE-loaded basophils from the blood of allergic patients (Example 5).
  • the testing of the rRh1 p 5 b mutants with epitope-mapped T cell clones confirms that the point mutations and deleting mutations react with, or fail to stimulate the TCLs in the expected manner (Example 6).
  • oligoclonal T cell lines which were established from the blood of patients who are allergic to grass pollen by means of stimulation with Ph1 p 5, it was possible to demonstrate that mutants are able to stimulate oligoclonal TCLs of this nature (Example 7). Taking the results of the reduction in allergenicity and the retention of the T cell stimulation together, the mutants, particularly the deletion mutants, constitute recombinant allergen variants which are potentially suitable for specific immunotherapy.
  • a solution of 100 g of an active compound or of an active compound mixture based on the modified recombinant allergens and 5 g of disodium hydrogen phosphate in 3 l of doubly distilled water is adjusted to pH 6.5 with 2N hydrochloric acid, sterilized by filtration, aliquoted into injection vials and lyophilized under sterile conditions: the vials are then sealed in a sterile manner.
  • Each injection vial comprises 5 mg of active compound.
  • a mixture of 20 g of an active compound in the form of the modified recombinant allergens together with 100 g of soya bean lecithin and 1400 g of cocoa butter is melted, poured into moulds and allowed to cool.
  • Each suppository comprises 20 mg of active compound.
  • a solution of 1 g of an active compound in the form of the modified recombinant allergens, 9.38 g of NaH 2 PO 4 2 H 2 O, 28.48 g of Na 2 HPO 4 . 12 H 2 O and 0.1 g of benz-alkonium chloride is prepared, in 940 ml of doubly distilled water. The solution is adjusted to pH 6.8, made up to 1.1 and sterilized by irradiation. This solution can be used in the form of eye drops.
  • 500 mg of an active compound in the form of the modified recombinant allergens are mixed with 99.5 g of yellow soft paraffin under aseptic conditions.
  • a mixture of 1 kg of active compound in the form of the modified recombinant allergens, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in the customary manner such that each tablet comprises 10 mg of active compound.
  • Tablets are compressed in analogy with Example E and are then coated, in a customary manner, with the coating consisting of sucrose, potato starch, talc, gum tragacanth and dye.
  • a solution of 1 kg of active compound in the form of the modified recombinant allergens in 60 l of doubly distilled water is sterilized by filtration aliquoted into ampoules and lyophilized under sterile conditions; the ampoules are then sealed in a sterile manner.
  • Each ampoule comprises 10 mg of active compound.
  • 14 g of active compound in the form of the modified recombinant allergens are dissolved in 10 l of an isotonic solution of NaCl and the solution is aliquoted into commercially available spraying vessels which are fitted with a pump mechanism.
  • the solution can be sprayed into the mouth or the nose.
  • One spraying stroke (approximately 0.1 ml) corresponds to a dose of approximately 0.14 mg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US09/381,903 1997-03-27 1998-03-16 Graminae pollen allergen mutants for specific immunotherapy, and production and use of the same Expired - Lifetime US6919086B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19713001A DE19713001A1 (de) 1997-03-27 1997-03-27 Graminaenpollenallergenmutanten zur spezifischen Immuntherapie, deren Herstellung und Verwendung
PCT/EP1998/001507 WO1998043657A2 (de) 1997-03-27 1998-03-16 Graminaenpollenallergenmutanten zur spezifischen immuntherapie, deren herstellung und verwendung

Publications (1)

Publication Number Publication Date
US6919086B1 true US6919086B1 (en) 2005-07-19

Family

ID=7824864

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/381,903 Expired - Lifetime US6919086B1 (en) 1997-03-27 1998-03-16 Graminae pollen allergen mutants for specific immunotherapy, and production and use of the same

Country Status (10)

Country Link
US (1) US6919086B1 (de)
EP (1) EP1009419B1 (de)
JP (2) JP4347418B2 (de)
AT (1) ATE327252T1 (de)
DE (2) DE19713001A1 (de)
ES (1) ES2264201T3 (de)
HU (1) HUP0001552A2 (de)
PL (1) PL196830B1 (de)
PT (1) PT1009419E (de)
WO (1) WO1998043657A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040166123A1 (en) * 2002-11-26 2004-08-26 Jacobi Henrik H. Allergen dosage form
US9975932B2 (en) 2010-01-14 2018-05-22 Merck Patent Gmbh Variants of group 5 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19713001A1 (de) * 1997-03-27 1998-10-01 Merck Patent Gmbh Graminaenpollenallergenmutanten zur spezifischen Immuntherapie, deren Herstellung und Verwendung
DE69940805D1 (de) 1998-01-31 2009-06-10 Sinai School Medicine Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie
WO2000052154A2 (en) * 1999-03-02 2000-09-08 The Board Of Trustees Of The University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US6572859B1 (en) 1999-10-29 2003-06-03 Pharmacia Diagnostics Ab Non-anaphylactic forms of grass pollen Phl p 6 allergen and their use
SE9903950D0 (sv) * 1999-10-29 1999-10-29 Pharmacia & Upjohn Diag Ab Non-anaphylactic forms of grass pollen allergen and their use
IT1318692B1 (it) * 2000-09-12 2003-08-27 Consiglio Nazionale Ricerche Varianti di proteine allergeniche di phleum pratense.
CZ20031653A3 (en) * 2000-11-16 2004-03-17 Alk-Abelló A/S Mutant allergens
AUPR779201A0 (en) * 2001-09-20 2001-10-11 University Of Melbourne, The Immunotherapeutic and immunoprophylactic reagents
SE0200946D0 (sv) * 2002-03-27 2002-03-27 Pharmacia Diagnostics Ab Novel Allergen
EP1356826A1 (de) 2002-04-22 2003-10-29 BIOMAY Produktions- und Handels- Aktiengesellschaft Mikropartikel die Kohlenhydratkugeln enthalten an welche ein Allergen kovalent gebunden sind
AU2004245184B2 (en) 2003-06-04 2011-03-24 Merck Patent Gmbh Phl p 5a derivatives with reduced allergenicity and retained T-cell reactivity
CN105001315A (zh) * 2010-01-14 2015-10-28 默克专利股份公司 由于脯氨酸残基突变而具有降低的致敏性的禾本科的第6组过敏原的变异体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006571A1 (en) 1989-11-03 1991-05-16 Immulogic Pharmaceutical Corporation A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor
WO1994004564A1 (en) 1992-08-14 1994-03-03 The University Of Melbourne T cell epitopes of ryegrass pollen allergen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19713001A1 (de) * 1997-03-27 1998-10-01 Merck Patent Gmbh Graminaenpollenallergenmutanten zur spezifischen Immuntherapie, deren Herstellung und Verwendung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006571A1 (en) 1989-11-03 1991-05-16 Immulogic Pharmaceutical Corporation A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor
WO1994004564A1 (en) 1992-08-14 1994-03-03 The University Of Melbourne T cell epitopes of ryegrass pollen allergen

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Abaza et al (Journal of Protein Chemistry. vol. 11. No. 5. 1992. pp. 433-444). *
Becker, W.M.: "Molekulare charakterisierung von Allergenen" Immun. Infekt., vol 22, 1994 pp. 82-87.
Bufe et al. (FEBS Letters 1995; 363: 6-12). *
Cao et al. (Allergy 1995 ; 50(suppl 25) : 37-44). *
Coleman et al. (Research in Immunology, 1994; 145(1): 33-36). *
Kuby et al., Immunology, 4th edition, 2000, Freeman, Publishers, New York, Table 16-1 and Figure 16-2 and p. 14. *
Lederman et al. (Molecular Immunology 28: 1171-1181, 1991). *
Li et al. (PNAS 77: 3211-3214, 1980). *
Maasch et al. (Clin. Rev. Allergy, 1987; 5:89-106). *
Mikayama et al. (PNAS, 1993, 90: 10056-10060). *
Muller W.D. et al.: "Group five allergens of timothy grass . . . "Int. Arch. Allergy Immunol., vol. 109, 1996 . pp. 353-355.
Ngo et al, in The Protein Folding Problem and Tertiary Structure Prediction, 1994. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495. *
Smith et al. (Molecular Immunolgy 1996; 33(4/5): 399-405). *
Vrtala et al. (J. Immunol, 1993; 151(9): 4773-4781). *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040166123A1 (en) * 2002-11-26 2004-08-26 Jacobi Henrik H. Allergen dosage form
US20080187558A1 (en) * 2002-11-26 2008-08-07 Alk-Abello A/S Allergen dosage form
US20080193535A1 (en) * 2002-11-26 2008-08-14 Alk-Abello A/S Allergen dosage form
US8329196B2 (en) 2002-11-26 2012-12-11 Alk-Abello A/S Allergen dosage form
US9408805B2 (en) 2002-11-26 2016-08-09 Alk-Abello A/S Allergen dosage form
US9415015B2 (en) 2002-11-26 2016-08-16 Alk-Abello A/S Allergen dosage form
US10080719B2 (en) 2002-11-26 2018-09-25 Alk-Abelló A/S Allergen dosage form
US10471008B2 (en) 2002-11-26 2019-11-12 Alk-Abelló A/S Allergen dosage form
US9975932B2 (en) 2010-01-14 2018-05-22 Merck Patent Gmbh Variants of group 5 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues

Also Published As

Publication number Publication date
PL196830B1 (pl) 2008-02-29
JP4347418B2 (ja) 2009-10-21
WO1998043657A3 (de) 1999-01-21
DE19713001A1 (de) 1998-10-01
DE59813556D1 (de) 2006-06-29
HUP0001552A2 (hu) 2000-09-28
JP5290671B2 (ja) 2013-09-18
EP1009419B1 (de) 2006-05-24
JP2002511842A (ja) 2002-04-16
EP1009419A2 (de) 2000-06-21
PL335981A1 (en) 2000-06-05
WO1998043657A2 (de) 1998-10-08
ATE327252T1 (de) 2006-06-15
PT1009419E (pt) 2006-10-31
JP2009062368A (ja) 2009-03-26
ES2264201T3 (es) 2006-12-16

Similar Documents

Publication Publication Date Title
JP5290671B2 (ja) 特異的免疫療法のためのイネ科花粉アレルゲン変異体及びそれらの製造及び使用
EP0671926B1 (de) Immunmodulierende peptide
EP1256352A2 (de) Immunomodulierende Peptide
WO2009022154A2 (en) Peptide with multiple epitopes
WO1994004171A9 (en) Immunomodulatory peptides
KR101519840B1 (ko) Ｆⅷ 펩타이드 및 혈우병 환자 내성화시 그의 용도
JP5926198B2 (ja) カバノキアレルギーに対するワクチン用ペプチド
WO1994004557A1 (en) Immunomodulatory peptides
Rogers et al. Recombinant Fel d I: Expression, purification, IgE binding and reaction with cat-allergic human T cells
US20160207967A1 (en) Phl p 5a derivatives having reduced allergeneity and retained t-cell reactivity
WO1998043657A9 (de) Graminaenpollenallergenmutanten zur spezifischen immuntherapie, deren herstellung und verwendung
JPH09504167A (ja) ドクムギ花粉アレルゲンのｔ細胞エピトープ
JPH07507924A (ja) アンブロシア・アルテミシフォリア由来の主要アレルゲンのｔ細胞エピトープ
US9005627B2 (en) Contiguous overlapping peptides for treatment of ragweed pollen allergy
RU2409589C2 (ru) ВАРИАНТ АЛЛЕРГЕНА ГРУППЫ I ИЗ Роасеае, ХАРАКТЕРИЗУЮЩИЙСЯ СНИЖЕННОЙ АЛЛЕРГЕННОСТЬЮ И СОХРАНЕННОЙ Т-КЛЕТОЧНОЙ РЕАКТИВНОСТЬЮ (ВАРИАНТЫ), КОДИРУЮЩАЯ ЕГО МОЛЕКУЛА ДНК И ЕГО ПРИМЕНЕНИЕ
WO2009095646A2 (en) Peptides from factor viii
RU2373283C2 (ru) Последовательность днк и рекомбинантное получение основных аллергенов группы 4 из злаковых
JP2015522584A (ja) アレルギーを予防又は治療するためのスギペプチド
US9850281B2 (en) Cladosporium peptides
JP2015520771A (ja) アルタナリアペプチド
WO2017134430A1 (en) Japanese pollen allergen peptides for preventing or treating allergy
JP2003533443A (ja) 潜在的な免疫優性アセチルコリン受容体アルファ・サブユニット・ペプチドの同定
Rogers Immunological Characterization of the Major Ragweed Allergens Amb a I and Amb a II Bruce L. Rogers, Julian F. Bond, Jay P. Morgenstern, Catherine M. Counsell, and Irwin J. Griffith
JP2003289887A (ja) 免疫調節ペプチド

Legal Events

Date Code Title Description
AS Assignment

Owner name: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KAHLERT, HELGA;STUWE, HANS-THOMAS;FIEBIG, HELMUT;AND OTHERS;REEL/FRAME:010744/0536

Effective date: 20000320

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12